Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Assessment of the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy. Antitumor activity will be evaluated on the basis of the progression-free survival status at 3 months.
Critère d'inclusion
- Recurrent or metastatic unresectable thymic carcinoma